Management and treatment of diabetes mellitus

Advances in Experimental Medicine and Biology

Volumn 771, Issue , 2013, Pages 356-380

  Imam, Khalid ^a  

^a CIVIL HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; BUFORMIN; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; PHENFORMIN; PIOGLITAZONE; REPAGLINIDE; RIMONABANT; ROSIGLITAZONE; SAXAGLIPTIN; SIBUTRAMINE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; VILDAGLIPTIN; ANTIDIABETIC AGENT;

ABDOMINAL DISCOMFORT; ACUTE HEMORRHAGIC PANCREATITIS; ACUTE KIDNEY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; ARTIFICIAL PANCREAS; BARIATRIC SURGERY; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES EDUCATION; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIARRHEA; DIET THERAPY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; EDEMA; EXERCISE; FACE EDEMA; FLATULENCE; FLUSHING; GENE THERAPY; GLYCEMIC CONTROL; HEADACHE; HEART INFARCTION; HEMORRHAGIC PANCREATITIS; HEPATITIS; HUMAN; HYPERSENSITIVITY; HYPOGLYCEMIA; HYPONATREMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; PANCREATITIS; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; SKIN EXFOLIATION; STEVENS JOHNSON SYNDROME; SUICIDAL BEHAVIOR; THYROID MEDULLARY CARCINOMA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; WEIGHT GAIN; WEIGHT REDUCTION; LIFESTYLE; METHODOLOGY; PATIENT EDUCATION; REVIEW; RISK FACTOR;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; PATIENT EDUCATION AS TOPIC; RISK FACTORS;

MLCS; MLOWN;

EID: 84874531111     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5441-0_26     Document Type: Article

References (122)

1. Steven RG. Emerging epidemic: diabetes in older adults: demography, economic impact, and pathophysiology. Diabetes Spectrum 2006; 19:221-228.
2. Norris SL, Zhang X, Avenell A et al. Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med 2004; 117:762.
3. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA 2003; 289(1):76-79.
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131):854-865.
5. Patel A et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24):2560-2572.
6. White NH, Danis RP, Davis MD et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 2011; 171(5):412-420.
7. Funnell MM, Brown TL, Childs BP et al. National standards for diabetes self-management education. Diabetes Care 2007; 30:1630.
8. Karter AJ, Parker MM, Moffet Hh et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006; 29(8): 1757-1763.
9. Goldstein DE, Little RR, Lorenz RA et al. Tests of glycemia in diabetes. Diabetes Care 2004; 27:1761.
10. Miller CK, Edwards L, Kissling G et al. Nutrition education improves metabolic outcomes among older adults with diabetes mellitus. Prev Med 2002; 34(2):252-259.
11. Bantle JP, Wylie-Rosett J, Albright AL et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008; 31 Suppl 1:S61.
12. Standards of medical care in diabetes. Diabetes Care 2010; 33 Suppl 1:S11.
13. Masharani U. Diabetes mellitus & hypoglycemia. In: McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis and Treatment 2010. McGraw-Hill: New York City, 2010:1079-1122.
14. Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115(1): 114-126.
15. Klein S, Burke LE, Bray GA et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity and Metabolism. Circulation 2004; 110(18):2952-2967.
16. Lawson ML, Kirk S, Mitchell T et al. One-year outcomes of Roux-en-Y gastric bypass for morbidly obese adolescents. J Pediatr Surg 2006; 41(1): 137-143.
17. O'Brien PE, Sawyer SM, Laurie C et al. Laparoscopic adjustable gastric banding in severely obese adolescents: a randomized trial. JAMA 2010; 303(6):519-526.
18. Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery. Am J Med 2009; 122:248-256.
19. Colquhoun AJ, Nicholson KG, Botha JL et al. Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect 1997; 119:335-341.
20. Bridges CB, Fukuda K, Uyeki TM et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2002; 51:1-31.
21. Fisher L, Skaff MM, Mullan JT et al. Clinical depression versus distress among patients with type 2 diabetes: not just a question of semantics. Diabetes Care 2007; 30:542-548.
22. Ismail K, Winkley K, Rabe-Hesketh S. Systematic review and meta-analysis of randomized controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. Lancet 2004; 363:1589.
23. Turner RC, Cull CA, Frighi V et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352(9131):837-853.
24. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281(21):2005-2012.
25. Nathan DM, Buse JB, Davidson MB et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193.
26. Monami M, Lamanna C, Marchionni N et al. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: Diabetes Res Clin Pract 2008; 79:196.
27. Bolen S, Feldman, L Vassy J et al. Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus. Ann Intern Med 2007; 147:386.
28. Zeller M, Danchin N, Simon D et al. Impact of type of pre-admission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010; 95(11):4993-5002.
29. Eurich DT, Simpson SH, Majumdar SR et al. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes. Pharmacotherapy 2005; 25:810-816.
30. Groop LC, Pelkonen R, Koskimies S et al. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 1986; 9:129-133.
31. Matthews DR, Cull CA, Stratton IM et al. UKPDS 26: sulphonylurea failure in non-insulin dependent diabetic patients over six years. Diabet Med 1998; 15:297-303.
32. Tessier D, Dawson K, Tetrault JP, Bravo G et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994; 11(10):974-980.
33. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17(6):467-473.
34. Arruda-Olson AM, Patch RK et al. Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. Mayo Clin Proc 2009; 84(1):28-33.
35. Langer O, Conway DL, Berkus MD et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343(16): 1134-1138.
36. Langer O, Yogev Y, Xenakis EM et al. Insulin and glyburide therapy: dosage, severity level of gestational diabetes, and pregnancy outcome. Am J Obstet Gynecol 2005; 192(1): 134-139.
37. Conway DL, Gonzales O, Skiver D. Use of glyburide for the treatment of gestational diabetes: the San Antonio experience. J Matern Fetal Neonatal Med 2004; 15:51.
38. Rochon M, Rand L, Roth L et al. Glyburide for the management of gestational diabetes: risk factors predictive of failure and associated pregnancy outcomes. Am J Obstet Gynecol 2006; 195:1090.
39. Fuhlendorff J, Rorsman P, Kofod H et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47(3):345-351.
40. Moses R, Slobodniuk R, Boyages S et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22(1): 11:9-24.
41. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333(9):541-549.
42. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574.
43. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131):854-865.
44. UKPDS 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310(6972):83-88.
45. Stumvoll M, Nurjhan N, Perriello G et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333(9):550-554.
46. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574.
47. Zhou G, Myers R, Li Y, Chen Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108(8): 1167-1174. http://reference.medscape.com/medline/abstract/20702526.
48. Kasia JL, Clifford JB, Silvio EI. Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. Diabetes Care 2011; 34:1431-1436.
49. Schernthaner G, Matthews DR, Charbonnel B et al. J Clin Endocrinol Metab 2004; 89(12):6068-6076.
50. Kipnes MS, Krosnick A, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus. Am J Med 2001; 111:10.
51. Schwartz S, Raskin P, Fonseca V et al. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998; 338(13):861-866.
52. Iwamoto Y, Kosaka K, Kuzuya T et al. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19(2): 151-156.
53. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106.
54. Vidal-Puig AJ, Considine RV, Jimenez-Linan M et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99(10):2416-2422.
55. Gervois P, Fruchart JC, Staels B. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab 2007; 3(2): 145-156.
56. Chiquette E, Ramirez G, Defronzo R. TI A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164(19):2097-2104.
57. Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28(7): 1547-1554.
58. Winkelmayer WC, Setoguchi S, Levin R et al. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008; 168(21):2368-2375.
59. Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 2007; 356:2457-2471. http://www.nejm.org/toc/nejm/356/24/.
60. Rosen CJ. The Rosiglitazone Story: Lessons from an FDA Advisory Committee Meeting. N Engl J Med 2007; 357:844-846. http://www.nejm.org/toc/nejm/357/9/.
61. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298(10): 1189-1195.
62. Winkelmayer WC, Setoguchi S, Levin R et al. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008; 168(21): 2368-2375.
63. Lewis JD, Ferrara A, Peng T et al. Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011; 34:916-922.
64. SDI, Vector One®: Total Patient Tracker (TPT). 2010-2010. Data extracted 10.
65. Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type I diabetes. Diabetes Care 1997; 20(3):248-253.
66. McCulloch DK, Kurtz AB, Tattersall RB. A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition. Diabetes Care 1983; 6(5):483-487.
67. Meneilly GS, Ryan EA, Radziuk J et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000; 23(8): 1162-1167.
68. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. Diabetes Care 1994; 17(6):561-566.
69. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years. Diabetes Care 1999; 22(6):960-964.
70. Chiasson JL, Josse RG, Hunt JA et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121(12):928-935.
71. Demuth HU, Mcintosh CH, Pederson RA. Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005; 1751(1):33-44.
72. Mannucci E, Ognibene A, Cremasco F et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001; 24(3):489-494.
73. Raz I, Hanefeld M, Xu L et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49(11):2564-2571.
74. Charbonnel B, Karasik A, Liu J et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29(12):2638-2643.
75. Rosenstock J, Brazg R, Andryuk PJ et al. Efficacy and safety ofthe dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy inpatients with type 2 diabetes. Clin Ther 2006; 28(10): 1556-1568.
76. Hermansen K, Kipnes M, Luo E et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9(5):733-745.
77. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity ofthe dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008; 10(5):376-386.
78. DeFronzo RA, Hissa MN, Garber AJ et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32(9): 1649-1655.
79. Chacra AR, Tan GH, Apanovitch A et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomized controlled trial. Int J Clin Pract 2009; 63(9): 1395-1406.
80. Pratley RE, Jauffret-Kamel S, Galbreath E et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38(6):423-428.
81. Pi-Sunyer FX, Schweizer A, Mills D et al. Efficacy andtolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76(1): 132-138.
82. Fonseca V, Schweizer A, Albrecht D et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50(6): 1148-1155.
83. Bosi E, Camisasca RP, Collober C et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30(4):890-895.
84. Eng J, Kleinman WA, Singh L et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267(11):7402-7405.
85. Parkes DG, Pittner R, Jodka C et al. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001; 50(5):583-589.
86. Kolterman OG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88(7): 3082-3089.
87. Xu G, Stoffers DA, Habener JF et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48(12):2270-2276.
88. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):1083-1091.
89. Zinman B, Hoogwerf BJ, Duran GS et al. The effect of adding exenatide to athiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146(7):477-485.
90. www.fda.gov/CDER/Drug/InfoSheets/HCP/exenatide2008HCP.htm. Accessed 2008.
91. Stephen JM, Maxine AP. Diabetes mellitus and hypoglycemia. Current Medical Diagnosis and Treatment 2010;1079-1121.
92. Linnebjerg H, Kothare PA, Skrivanek Z et al. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes. Diabet Med 2006; 23(3):240-245.
93. Vilsboll T, Zdravkovic M, Le-Thi T et al. Liraglutide, along-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30:1608.
94. Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes. Diabetes Care 2009; 32(7): 1224-1230.
95. Bjerre Knudsen L, Madsen LW, Andersen S et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151 (4): 1473-1486.
96. Ratner RE, Dickey R, Fineman M et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: one year, randomized controlled trial. Diabet Med 2004; 21(11): 1204-1212.
97. Hollander PA, Levy P, Fineman MS et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26(3):784-790.
98. Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988; 81(2):442-448.
99. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 7(2): 188-199.
100. Kitabchi AE, Umpierrez GE, Murphy MB et al. Management of hyperglycemic crises in patients with diabetes (Technical Review). Diabetes Care. 2001; 24:131-153.
101. Greenspan FS, Gardner DG. Basic and Clinical Endocrinology. Sixth edition 2001; 661-668.
102. Barnett AH, Owens DR. Insulin analogues. Lancet 1997; 349:47.
103. Singh SR, Ahmad F, Lai A et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009; 180:385.
104. Heinemann L, Linkeschova R, Rave K et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23(5):644-649.
105. Home PD, Lagarenne P. Combined randomized controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009; 52(12):2499-506.
106. Havelund S, Plum A, Ribel U et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004; 21:1498.
107. Philis-Tsimikas A, Charpentier G, Clauson P et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28(10):1569-1581.
108. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26(11):3080-3086.
109. Plank J, Siebenhofer A, Berghold A et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005; 165(12): 1337-1344.
110. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963.
111. Bergenstal RM, Johnson M, Powers MA et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 2008; 31(7):1305-1310.
112. Castéra V, Dutour-Meyer A, Koeppel M et al. Systemic allergy to human insulin and its rapid and long acting analogs: successful treatment by continuous subcutaneous insulin lispro infusion. Diabetes Metab 2005;31:391-400.
113. van Bon AC, Brouwer TB, von Basum G et al. Future Acceptance of an Artificial Pancreas in Adults with Type 1 Diabetes. Diabetes Technol Ther 2011; 13(7):731-736.
114. Nagaya M, Katsuta H, Kaneto H et al. Adult mouse intrahepatic biliary epithelial cells induced in vitro to become insulin-producing cells. J Endocrinol 2009; 201:37-47.
115. Alejandro R, Barton FB, Hering BJ et al. Update from the Collaborative Islet Transplant Registry. Transplantation 2008; 86:1783-1788.
116. Ojo AO, Meier-Kriesche HU, Hanson JA et al. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation 2001; 71:82-90.
117. Larsen. Pancreas transplantation: indications and consequences. Endocr Rev 2004; 25:919-946.
118. Lee HC, Kim SJ, Kim KS et al. Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue. Nature 2000; 408:483-488.
119. Rahmoune H, Thompson PW, Ward JM et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin dependent diabetes. Diabetes 2005; 54:3427-3434.
120. Handelsman Y, Goldberg RB, Garvey WT et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: arandomized, prospective study. Endocr Pract 2010; 16(4):617-628. http://reference.medscape.com/medline/abstract/20634176.
121. Bonadonna RC, Heise T, Arbet-Engel et al. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 2010; 95(11):5028-5036. http://reference.medscape.com/medline/abstract/20739378.
122. http://en.wikipedia.org/wiki/Insulin-therapy#cite-note-24.